Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

About this update from Artelo Biosciences, Inc.

The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13, the Company's peripherally selective cannabinoid agonist currently being evaluated in the Phase 2 CAReS trial for cancer-related anorexia and the Phase 2 DREAM study in patients with glaucoma or ocular hypertension. The allowed claims protect compositions of ART27.13 dispersed in polyethylene glycol, including the Company's intended commercial formulation. This development marks a major milestone in Artelo's global intellectual property strategy and positions the Company for long-term value creation. "This U.S. Notice of Allowance and near-term expectation of the issuance of the patent further strengthens the intellectual property foundation supporting ART27.13 and its long-term development potential," said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. "As ART27.13 advances in multiple Phase 2 studies, we believe protecting the intended commercial formulation is an important step in building value around the program and preserving opportunities across multiple indications." ART27.13 is being evaluated in the Phase 2 portion of CAReS trial targeting cancer-related anorexia. The investigational drug was well tolerated in the Phase 1 stage and showed early signs of stabilizing or reversing weight loss in more than 60% of participants. Interim results from the Phase 2 portion of CAReS demonstrated the ability of the drug to reverse cancer-related anorexia in all patients taking the highest dose whereas the all the participants on placebo continued to lose weight throughout the study. ART27.13 is also being evaluated in the DREAM study, a Phase 2 in patients with glaucoma or ocular hypertension. The investigator-led study, funded by Glaucoma UK and the HSC R&D Division, is evaluating ART27.13's potential as a...

View stock analysis, news, and events for Artelo Biosciences, Inc.